1,461
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Role of recombinant factor VIIa in the clinical management of severe postpartum hemorrhage: consensus among European experts

, , , , , , , , , & show all
Article: 2332794 | Received 16 Feb 2024, Accepted 13 Mar 2024, Published online: 27 Mar 2024

References

  • Park SC, Yeom SR, Han SK, et al. Recombinant activated factor VII as a second line treatment for postpartum hemorrhage. Korean J Crit Care Med. 2017;32(4):1–8. doi: 10.4266/kjccm.2016.00787.
  • Chauke L, Bhoora S, Ngene NC, et al. Postpartum hemorrhage – an insurmountable problem? Case Rep Womens Health. 2023;37:e00482. doi: 10.1016/j.crwh.2023.e00482.
  • Gallos I, Devall A, Martin J, et al. Randomized trial of early detection and treatment of postpartum hemorrhage. N Engl J Med. 2023;389(1):11–21. doi: 10.1056/NEJMoa2303966.
  • Bienstock JL, Eke AC, Hueppchen NA, et al. Postpartum hemorrhage. N Engl J Med. 2021;384(17):1635–1645. doi: 10.1056/NEJMra1513247.
  • Knight M, Bunch K, Patel R, et al. Saving lives, improving mothers’ care core report – lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2019–21. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2023.
  • Evensen A, Anderson JM, Fontaine P, et al. Postpartum hemorrhage: prevention and treatment. Am Fam Physician. 2017;95(7):442–449.
  • Welsh A, McLintock C, Gatt S, et al. Guidelines for the use of recombinant activated factor VII in massive obstetric hemorrhage. Aust N Z J Obstet Gynaecol. 2008;48(1):12–16. doi: 10.1111/j.1479-828X.2007.00823.x.
  • Magon N, Babu K. Recombinant factor VIIa in post-partum hemorrhage: a new weapon in obstetrician’s armamentarium. N Am J Med Sci. 2012;4(4):157–162. doi: 10.4103/1947-2714.94938.
  • Alfirevic Z, Elbourne D, Pavord S, et al. Use of recombinant activator factor VII in primary postpartum hemorrhage. Obstet Gynecol. 2007;110(6):1270–1278. doi: 10.1097/01.AOG.0000288515.48066.99.
  • Surbek D, Vial Y, Girard T, et al. Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion. Arch Gynecol Obstet. 2020;301(2):627–641. doi: 10.1007/s00404-019-05374-8.
  • Schlemback D, Helmer H, Henrich W, et al. Peripartum haemorrhage, diagnosis and therapy. Guideline of the DGGG and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). Geburtshilfe Frauenheilkd. 2018;78:382–399.
  • Committee for Medicinal Products for Human Use (CHMP). CHMP extension of indication variation assessment report (rFVII®, Eptacog Alfa), European Public Assessment Report (EPAR); 2022 [cited 2022 Apr 22]. Procedure No. EMEA/H/C/000074/II/0116.
  • NovoSeven (Eptacog Alfa) Summary of Product Characteristics; 2023; [cited 2023 Nov]. Available from: https://www.ema.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf
  • Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542–547. doi: 10.1046/j.1365-2141.1997.4463256.x.
  • Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015;13(4):520–529. doi: 10.1111/jth.12844.
  • Sørensen B, Dargaud Y, Kenet G, et al. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia. 2012;18(2):255–262. doi: 10.1111/j.1365-2516.2011.02612.x.
  • Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl. 1998;63:7–10. doi: 10.1111/j.1600-0609.1998.tb01103.x.